In a later work, constitutive expression of OCT4, KLF4, and SOX2 in BRAF-mutant HT-144 human melanoma cells produced metastable iPSCs with reduced tumorigenicity and therapeutic resistance against MAPK inhibitors. This evidence concerns the gene KLF4 and melanoma.